Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.13)
# 1,228
Out of 4,755 analysts
192
Total ratings
43.4%
Success rate
1.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences | Maintains: Overweight | $170 → $185 | $116.85 | +58.32% | 25 | Feb 4, 2025 | |
PTCT PTC Therapeutics | Upgrades: Overweight | $45 → $67 | $48.64 | +37.76% | 10 | Dec 13, 2024 | |
FOLD Amicus Therapeutics | Downgrades: Equal-Weight | $17 → $12 | $9.57 | +25.39% | 4 | Dec 13, 2024 | |
BIOA BioAge Labs | Initiates: Overweight | $40 | $4.34 | +821.66% | 1 | Oct 21, 2024 | |
ITCI Intra-Cellular Therapies | Maintains: Overweight | $92 → $95 | $127.56 | -25.53% | 5 | Oct 11, 2024 | |
CNTA Centessa Pharmaceuticals | Upgrades: Overweight | $11 → $26 | $17.26 | +50.64% | 1 | Sep 19, 2024 | |
ENGN enGene Holdings | Maintains: Overweight | $40 | $6.32 | +532.91% | 2 | Sep 11, 2024 | |
ACAD ACADIA Pharmaceuticals | Downgrades: Equal-Weight | $28 → $20 | $18.49 | +8.17% | 23 | Aug 7, 2024 | |
CRVO CervoMed | Initiates: Overweight | $35 | $2.13 | +1,543.19% | 1 | Jul 26, 2024 | |
JAZZ Jazz Pharmaceuticals | Maintains: Equal-Weight | $160 → $150 | $129.98 | +15.40% | 4 | Jul 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $34.93 | +100.40% | 2 | May 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $7.88 | +217.26% | 1 | Apr 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $40 | $54.07 | -26.02% | 5 | Apr 2, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $27.52 | +99.85% | 1 | Feb 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $60 → $90 | $41.56 | +116.55% | 12 | Jan 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.92 | +334.74% | 10 | Dec 19, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $2.65 | +50.94% | 1 | Dec 19, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $55 | $57.58 | -4.48% | 10 | Dec 19, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.68 | +138.10% | 1 | Dec 19, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $60 → $140 | $6.05 | +2,214.05% | 1 | Dec 8, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $84 | $43.58 | +92.75% | 7 | Nov 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $40 | $11.64 | +243.64% | 4 | Nov 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $1.80 | +677.78% | 3 | Aug 4, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $1.39 | +259.71% | 1 | Jul 11, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.79 | +67.60% | 8 | Mar 20, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.18 | +1,086.44% | 7 | Feb 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $19 | $9.81 | +93.68% | 5 | Feb 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 | $1.58 | +849.37% | 2 | Feb 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.97 | +407.61% | 3 | Jan 30, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $32.81 | -32.95% | 10 | Nov 2, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $42.53 | +249.17% | 2 | May 11, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $3.31 | +1,712.69% | 5 | Aug 13, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.21 | +42.69% | 9 | Apr 19, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.75 | +7,071.31% | 6 | May 8, 2020 |
Neurocrine Biosciences
Feb 4, 2025
Maintains: Overweight
Price Target: $170 → $185
Current: $116.85
Upside: +58.32%
PTC Therapeutics
Dec 13, 2024
Upgrades: Overweight
Price Target: $45 → $67
Current: $48.64
Upside: +37.76%
Amicus Therapeutics
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $9.57
Upside: +25.39%
BioAge Labs
Oct 21, 2024
Initiates: Overweight
Price Target: $40
Current: $4.34
Upside: +821.66%
Intra-Cellular Therapies
Oct 11, 2024
Maintains: Overweight
Price Target: $92 → $95
Current: $127.56
Upside: -25.53%
Centessa Pharmaceuticals
Sep 19, 2024
Upgrades: Overweight
Price Target: $11 → $26
Current: $17.26
Upside: +50.64%
enGene Holdings
Sep 11, 2024
Maintains: Overweight
Price Target: $40
Current: $6.32
Upside: +532.91%
ACADIA Pharmaceuticals
Aug 7, 2024
Downgrades: Equal-Weight
Price Target: $28 → $20
Current: $18.49
Upside: +8.17%
CervoMed
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $2.13
Upside: +1,543.19%
Jazz Pharmaceuticals
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $160 → $150
Current: $129.98
Upside: +15.40%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $34.93
Upside: +100.40%
Apr 30, 2024
Initiates: Overweight
Price Target: $25
Current: $7.88
Upside: +217.26%
Apr 2, 2024
Maintains: Equal-Weight
Price Target: $75 → $40
Current: $54.07
Upside: -26.02%
Feb 20, 2024
Initiates: Overweight
Price Target: $55
Current: $27.52
Upside: +99.85%
Jan 5, 2024
Downgrades: Equal-Weight
Price Target: $60 → $90
Current: $41.56
Upside: +116.55%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.92
Upside: +334.74%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $2.65
Upside: +50.94%
Dec 19, 2023
Upgrades: Overweight
Price Target: $29 → $55
Current: $57.58
Upside: -4.48%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.68
Upside: +138.10%
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $60 → $140
Current: $6.05
Upside: +2,214.05%
Nov 3, 2023
Maintains: Overweight
Price Target: $90 → $84
Current: $43.58
Upside: +92.75%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $11.64
Upside: +243.64%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $1.80
Upside: +677.78%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $1.39
Upside: +259.71%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.79
Upside: +67.60%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.18
Upside: +1,086.44%
Feb 3, 2023
Maintains: Overweight
Price Target: $27 → $19
Current: $9.81
Upside: +93.68%
Feb 3, 2023
Upgrades: Overweight
Price Target: $15
Current: $1.58
Upside: +849.37%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.97
Upside: +407.61%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $32.81
Upside: -32.95%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $42.53
Upside: +249.17%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $3.31
Upside: +1,712.69%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.21
Upside: +42.69%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.75
Upside: +7,071.31%